Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial.

Bipolar affective disorders often require adjunctive therapy to treat persistent symptoms. In order to evaluate bipolar symptoms inadequately responsive to lithium, we have compared the effects of two structurally related compounds carbamazepine (CBZ) and oxcarbazepine (OXC). We evaluated the efficacy and safety of CBZ and OXC administration in residual symptoms as an adjunctive therapy in Bipolar I (BP I) and Bipolar II (BP II) patients while on lithium maintenance treatment. We selected from 153 bipolar patients in treatment those fulfilling Research Diagnostic Criteria for mania or hypomania, according to the SADS-L and conducted in 52 bipolar patients (27 BP I, 25 BP II) a double-blind, randomized, parallel-group, single centre, clinical trial. Bipolar I and II outpatients, were randomly assigned on a 1:1 ratio to OXC (n=26) or CBZ (n=26) for an 8-week period as add-on treatment to the existing lithium regimen. Outcome measures included the Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale 21 items (HDRS-21) and Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impression severity (CGI-S) and improvement illness (CGI-I). These scales were administered at baseline and at the end of weeks 2, 4 and 8. All the fifty-two patients completed the trial. Overall, females were 35 (65%) and mean (S.D.) age was 39.4 (11.9) years; final doses at the end of week 8 in OXC group was 637.7 (210) mg/day and in the CBZ group 673.5 (179) mg/day; lithium plasma levels were 0.73 (0.25) meq/l and 0.71 (0.28) meq/l, respectively. Both OXC and CBZ were effective in reducing bipolar scores from baseline to endpoint (p<0.01). OXC was more effective than CBZ at weeks 4 and 8 on all 5 outcome measures. OXC resulted in greater significant mean reductions in YMRS, HDRS-21, MADRS, CGI-S and CGI-I scores from baseline to week 4 (p<0.05) and from baseline to week 8 (p<0.001), except YMRS (p<0.01). OXC appeared to be significantly more effective and with better tolerability than CBZ as add-on strategy treatment in BP I and BP II patients. This pilot, randomized clinical trial, suggests the potential usefulness of OXC as adjunctive therapy to lithium both in acute and long-term treatment of bipolar disorder. However, further adequately placebo-controlled trials are needed to expand these findings.

Mirtazapine versus fluoxetine in the treatment of panic disorder.

Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder. The present study compared the effect of mirtazapine and fluoxetine in the treatment of panic disorder in a double-blind, randomized, flexible-dose trial conducted with outpatients. After a 1-week single-blind placebo run-in, 27 patients entered an 8-week double-blind phase in which they were randomly assigned to treatment with either mirtazapine or fluoxetine. Both groups improved significantly in all but one efficacy measure (P < or = 0.01). ANOVA showed no significant differences between the two treatment groups in number of panic attacks, Hamilton Anxiety Scale or Sheehan Phobic Scale, whereas measures of patient global evaluation of phobic anxiety were significantly different between groups (F1,20 = 6.91, P = 0.016) favoring mirtazapine. For the 22 patients who completed the study, the mean daily dose of mirtazapine was 18.3 +/- 1.3 vs 14.0 +/- 1.0 mg for fluoxetine at the endpoint. Weight gain occurred more frequently in the mirtazapine group (50 vs 7.7%, P = 0.04) and nausea and paresthesia occurred more often in the fluoxetine group (P = 0.01). Results suggest that mirtazapine has properties that make it attractive for the treatment of panic disorder.

Mirtazapine versus fluoxetine in the treatment of panic disorder

Mirtazapine is an antidepressant whose side effect profile differs from that of first-line agents (selective serotonin reuptake inhibitors) used in the treatment of panic disorder. The present study compared the effect of mirtazapine and fluoxetine in the treatment of panic disorder in a double-blind, randomized, flexible-dose trial conducted with outpatients. After a 1-week single-blind placebo run-in, 27 patients entered an 8-week double-blind phase in which they were randomly assigned to treatment with either mirtazapine or fluoxetine. Both groups improved significantly in all but one efficacy measure (P<=0.01). ANOVA showed no significant differences between the two treatment groups in number of panic attacks, Hamilton Anxiety Scale or Sheehan Phobic Scale, whereas measures of patient global evaluation of phobic anxiety were significantly different between groups (F1,20 = 6.91, P = 0.016) favoring mirtazapine. For the 22 patients who completed the study, the mean daily dose of mirtazapine was 18.3 + or - 1.3 vs 14.0 + or - 1.0 mg for fluoxetine at the endpoint. Weight gain occurred more frequently in the mirtazapine group (50 vs 7.7 percent, P = 0.04) and nausea and paresthesia occurred more often in the fluoxetine group (P = 0.01). Results suggest that mirtazapine has properties that make it attractive for the treatment of panic disorder

ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments.

OBJECTIVE: To evaluate the prevalence, comorbid conditions, and impairments of attention-deficit/hyperactivity disorder (ADHD) among young adolescents in Porto Alegre, Brazil. METHOD: 1,013 students aged 12 to 14 years were evaluated at 64 state schools, using a screening instrument based on the 18 DSM-IV ADHD symptoms. All positive screened students (n = 99) and a random subset of negative screened subjects (n = 92) had a psychiatric evaluation carried out within a hospital setting or at home. RESULTS: The prevalence of ADHD was estimated to be 5.8% (95% confidence interval = 3.2-10.6), and the comorbidity with other disruptive behavior disorders was high (47.8%). Youths with ADHD (n = 23) had significantly higher rates of school repetitions, suspensions, and expulsions (p < .01) than controls (n = 168). No association was identified between ADHD and alcohol, marijuana, and inhalant use. CONCLUSION: The results extend to adolescents well-documented findings in children, indicating that ADHD is quite prevalent in early adolescence and affected youths are at high risk for impairment and dysfunction in multiple domains.

Clozapina no Brasil: avaliação da aplicabilidade do sistema de farmacovigilância e resultados terapêuticos preliminares / Clozapine in Brazil: evaluation of the feasibility of the drug surveillance system and preliminary therapeutic results

É apresentado o resultado de um estudo multicêntrico brasileiro cujos objetivos foram: aplicar em condições reais o modelo de farmacovigilância da clozapina no país (Sistema de Farmacovigilância de Leponex ð SFL) para detectar e corrigir eventuais falhas e proporcionar a diversos psiquiatras a experiência com o medicamento dentro das normas de segurança do SFL. Foram estudados 34 pacientes com diagnóstico de esquizofrenia crônica, refratários e/ou intolerantes ao tratamento com neurolépticos, que apresentavam exames hematológicos dentro dos parâmetros exigidos pelo SFL. A avaliação da eficácia antipsicótica da CZP foi feita pela BPRS e pela CGI e a tolerabilidade geral foi avalidada pela escala UKU, ao lado da avaliação hematológica semanal nas primeiras 18 semanas e mensal nos meses subseqüentes. O tratamento com a CZP incluiu doses crescentes e variáveis, tendo sido observado, ao final dos seis meses de tratamento, que a dose de manutenção se situava entre 75 e 700mg (mediana de 400mg). A análise da média dos escores da BPRS mostrou que houve melhora estatisticamente significante dos sintomas (ANOVA F = 112,24; p < 0,001), e essa diferença estatística ocorreu a partir do primeiro mês de tratamento. A avaliação préðtratamento, mostrou que houve redução significante da gravidade da doença, com remissão em 14,7 por cento (5/34) e melhora parcial em 70 por cento (24/34). Com relação à tolerabilidade, destacaðse a ausência de reações extrapiramidais bem como a boa adesão à rotina de controles hematológicos; um paciente apresentou trombocitopenia, que levou à interrupção da CZP, e outro interrompeu o tratamento devido a efeitos colaterais nãoðhematológicos. Os autores concluem que o efeito terapêutico da CZP foi promissor e ressaltam o bom resultado obtido com a operacionalização do SFL no Brasil

Clozapina no Brasil: avaliacao da aplicabilidade do sistema de farmacovigilancia e resultado terapeuticos preliminares

E apresentado o resultado de um estudo multicentrico brasileiro cujos objetivos foram: aplicar em condicoes reais o modelo da farmacovigilancia da clozapina no pais (Sistema de Farmacovigilancia de Leponex - SFL) para detectar e corrigir eventuais falhas e proporcionar a diversas psiquiatras a experiencia com o medicamento dentro das normas de seguranca do SFL. Foram estudados 34 pacientes com diagnostico de esquizofrenia cronica, refratarios e/ou intolerantes ao tratamento com neurolepticos, que apresentavam exames hermatologicos dentro dos parametros exigidos pelo SFL. A avaliacao da eficacia antipsicotica da CZP foi feita pela BPRS e pela CGI e a tolerabilidade geral foi avaliada pela escala UKU, ao lado da avaliacao hematologica semanal nas primeiras 18 semanas e mensal nos meses subsequentes. O tratamento com a CZP incluiu doses crescentes e variaveis, tendo sido observado, ao final dos seis meses de tratamento, que a dose de manutencao se situava entre 75 e 700mg (mediana de 400mg). A analise da media dos escores da BPRS mostrou que houve melhora estatisticamente significante dos sintomas (ANOVA F=112,24; p<0,001), e essa diferenca estatistica ocorreu a partir do primeiro mes de tratamento. A avaliacao final dos pacientes, em comparacao a avaliacao pre-tratamento, mostrou que houve reducao significante da gravidade da doenca, com remissao em 14,7 por cento (5/34) e melhora parcial em 70 por cento (24/34). Com relacao a tolerabilidade, detaca-se a ausencia de reacoes extrapiramidais bem como a boa adesao a rotina de controles hematologicos; um paciente apresentou trombocitopenia, que levou a interrupcao da CZP, e outro interrompeu o tratamento devido a efeitos colaterais nao-hematologicos. Os autores concluem que o efeito terapeutico da CZP foi promissor e ressaltam o bom resultado obtido com a operacionalizacao do SFL no Brasil.